World Cancer Immunotherapy Market Research 2023-2027: Curing Cancer is Generating Enormous New Opportunities - Outcome Potential, Technology Environment, Target Solutions
PR Newswire
DUBLIN, March 15, 2024
DUBLIN, March 15, 2024 /PRNewswire/ -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.
Are cures for cancer in sight? What is the opportunity in this market? What companies are poised to benefit? Is disruption a possibility? Find out in this comprehensive report.
A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR-T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027.
Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. Make investment decisions and valuations with confidence using the latest data.
Key Topics Covered:
1 Market Guides
1.1 Situation Analysis
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants
2 Introduction and Market Definition
2.1 What is Cancer Immunotherapy?
2.2 Immunotherapy - the looming cures
2.3 Market Definition
2.3.1 Market Size
2.3.2 Currency
2.3.3 Years
2.4 Methodology
2.4.1 Methodology
2.4.2 Sources
2.4.3 Authors
2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective
2.5.1 Global Expenditures for Medicines
3 Immunotherapy - Guide to Immune Technologies
3.1 The Immune System
3.1.1 Innate immune system
3.1.1.1 Surface barriers
3.1.1.2 Inflammation
3.1.1.3 Complement system
3.1.1.4 Cellular barriers
3.1.1.5 Natural killer cells
3.1.2 Adaptive immune system
3.1.2.1 Lymphocytes
3.1.2.2 Killer T cells
3.1.2.3 Helper T cells
3.1.2.4 Gamma delta T cells
3.1.2.5 B lymphocytes and antibodies
3.1.3 Tumor immunology - the immune surveillance system
3.2 Immuno Oncology Technologies
3.2.1 Monoclonal Antibodies
3.2.1.1 Outlook for Monoclonal Antibodies
3.2.1.2 Companies with Monoclonal Antibodies in their Pipeline
3.2.2 Cancer vaccines
3.2.2.1 Outlook for Cancer Vaccines
3.2.2.2 Companies with Cancer Vaccines in their Pipeline
3.2.3 Cytokines
3.2.3.1 Outlook for Cytokines
3.2.3.2 Companies with Cytokines in their Pipeline
3.2.4 Cell Based Therapies
3.2.4.1 Outlook for Cell Based Therapies
3.2.4.2 Companies with Cell Based Therapies in their Pipeline
3.2.5 Inhibitors/Agonists
3.2.5.1 Outlook for Inhibitors/Agonists
3.2.5.2 Companies with Inhibitors/Agonists in their Pipeline
3.2.6 Antibody Drug Conjugates
3.2.6.1 Outlook for Antibody Drug Conjugates
3.2.6.2 Companies with Antibody Drug Conjugates in their Pipeline
3.2.7 Others
3.2.7.1 Outlook for Other Therapeutics
3.2.7.2 Companies with Viral Therapeutics in their Pipeline
3.2.7.3 Companies with Other Therapeutics in their Pipeline
4 Industry Overview
4.1 Market Players - Roles & Impacts
4.1.1 Drug manufacturers - Larger/pharmaceutical
4.1.2 Drug manufacturers - Generic
4.1.3 Contract Research and Manufacturing
4.1.4 In Vitro Diagnostics Industry
4.1.5 Drug Marketing Companies
4.1.6 Biotechnology Companies
4.1.7 Regulatory Bodies
5 Market Trends
5.1 Factors Driving Growth
5.1.1 Outcome potential
5.1.2 Fast tracking
5.1.3 Funding
5.1.4 Technology Environment
5.1.5 Target Solutions
5.2 Factors Limiting Growth
5.2.1 Cost of Treatment
5.2.2 Clinical Trials Role
5.2.3 Combinations
5.2.4 Protocols
5.3 Therapeutic Technology Development
5.3.1 Combinations - Issues and Complexity
5.3.2 Preference for a drug
5.3.3 Problems of Immunity Engineering
5.3.4 The Role of Cost
5.3.5 The Disruption Dynamic
5.3.6 CAR-T Cell Therapy
5.3.7 The Next Five Years
6 Cancer Immunotherapy Recent Developments
6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 Continued Success with Immunotherapy in Melanoma
6.3 AC Immune Receives FDA Fast Track Designation
6.4 LTZ Announces Financing
6.5 Immunotherapy for Cancer Overview
6.6 Implantable device shrinks pancreatic tumors
6.7 mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence
6.8 Towards a Universal Cancer Immunotherapy
6.9 New Strategy May Improve T-Cell Therapy in Solid Tumors
6.10 Immunotherapy linked to increase in Medicare spending
6.11 Immunotherapy Effective with Ovarian Cancer
6.12 Cancer Immunotherapy Granted Fast Track
7 Profiles of Key Immunotherapy Companies
7.1 AbbVie
7.2 Achilles Therapeutics
7.3 Acumen Pharmaceuticals
7.4 Adagene
7.5 Adaptimmune Therapeutics
7.6 Adicet Bio
7.7 ALX Oncology Holdings
7.8 Ambrx Biopharma
7.9 Amgen
7.10 Apexigen
7.11 Arcus Biosciences
7.12 argenx
7.13 AstraZeneca
7.14 Atreca
7.15 Avalo Therapeutics
7.16 Avid Bioservices
7.17 Bavarian Nordic
7.18 BioAtla
7.19 Biogen Inc.
7.20 BioNTech
7.21 Bolt Biotherapeutics
7.22 Bristol-Myers Squibb
7.23 Candel Therapeutics
7.24 Caribou Biosciences
7.25 Celldex Therapeutics
7.26 Checkpoint Therapeutics
7.27 Chinook Therapeutics
7.28 Corvus Pharmaceuticals
7.29 Cullinan Oncology
7.30 Eli Lilly
7.31 EOM Pharmaceuticals
7.32 Evaxion Biotech
7.33 Genenta Science
7.34 Gilead Sciences
7.35 Gracell Biotechnologies
7.36 Greenwich LifeSciences
7.37 Gritstone bio
7.38 Harpoon Therapeutics
7.39 ImmunityBio
7.40 Immunocore Holdings
7.41 Immunome
7.42 IMV Inc
7.43 Incyte
7.44 Indaptus Therapeutics
7.45 Instil Bio
7.46 Iovance Biotherapeutics
7.47 Johnson & Johnson
7.48 Marker Therapeutics
7.49 Medicenna Therapeutics
7.50 Merck & Co.
7.51 Merus
7.52 Moderna
7.53 Mustang Bio
7.54 Nanobiotix
7.55 Neoleukin Therapeutics
7.56 Novartis
7.57 Novavax
7.58 Oncorus
7.59 PDS Biotechnology
7.60 Pfizer
7.61 Regeneron Pharmaceuticals
7.62 Roche
7.63 Sanofi
7.64 Sensei Biotherapeutics
7.65 Senti Biosciences
7.66 Surface Oncology
7.67 Takeda Pharmaceutical
7.68 TC Biopharm
7.69 ThermoGenesis Holdings
7.70 UroGen Pharma
7.71 Werewolf Therapeutics
7.72 Xilio Therapeutics
7.73 Zymeworks
8 The Global Market for Immuno-Oncology Therapeutics
8.1 Global Market Overview by Country
8.2 Global Market by Therapy - Overview
8.3 Global Market by Cancer - Overview
8.4 Global Market by Customer - Overview
9 Global Immuno-Oncology Therapy Markets - By Therapy
9.1 MAB
9.2 Cytokine
9.3 Vaccine
9.4 Cell Based
9.5 Inhibitor/Agonist
9.6 Other IO Therapy
10 Global Immuno-Oncology Therapeutic Markets - By Cancer
10.1 Breast
10.2 ColoRectal
10.3 Cervical
10.4 Lung
10.5 Precancer
10.6 Prostate
10.7 Melanoma
10.8 Blood
10.9 Other Cancer
11 Global Immuno-Oncology Therapeutic Markets - By Customer
11.1 Pharma
11.2 Clinic
11.3 Other Customer
12 Appendices
12.1 FDA Cancer Drug Approvals by Year
12.2 Clinical Trials Started
12.3 Prevalence of Cancer Treatments
For more information about this report visit https://www.researchandmarkets.com/r/svnzer
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:SOURCE Research and Markets
